Barriers and enablers to implementing antenatal magnesium sulphate for fetal neuroprotection guidelines: A study using the theoretical domains framework

Emily Bain; Tanya Bubner; Philippa Middleton; Pat Ashwood; Emer Van Ryswyk; Lucy Simmons; Sally Reid; Caroline A Crowther

doi:10.1111/jpc.12884_2

Barriers and enablers to implementing antenatal magnesium sulphate for fetal neuroprotection guidelines: A study using the theoretical domains framework

Emily Bain, Tanya Bubner, Philippa Middleton, Pat Ashwood, Emer Van Ryswyk, Lucy Simmons, Sally Reid, Caroline A Crowther

College of Medicine and Public Health

Research output: Contribution to journal › Meeting Abstract › peer-review

Abstract

Strong evidence supports the use of antenatal magnesium sulphate before birth at less than 30 weeks’ gestation to reduce the risk of death and cerebral palsy for very preterm babies. This study was undertaken to assess health professionals’ self reported use of this neuroprotective therapy, and barriers and enablers to implementation of Australian and New Zealand clinical practice guidelines.

Original language	English
Pages (from-to)	30
Number of pages	1
Journal	Journal of Paediatrics and Child Health
Volume	51
Issue number	Suppl 1
DOIs	https://doi.org/10.1111/jpc.12884_2
Publication status	Published - Apr 2015
Event	Perinatal Society of Australia and New Zealand 19th Annual Congress - Crown Promenade, Melbourne, Australia Duration: 19 Apr 2015 → 22 Apr 2015 Conference number: 19

Keywords

fetal neuroprotection
Antenatal care
magnesium sulphate
neuroprotective therapy

Access to Document

10.1111/jpc.12884_2Licence: In Copyright

Cite this

@article{e5daf8237a0545c59a39e0d47156a976,

title = "Barriers and enablers to implementing antenatal magnesium sulphate for fetal neuroprotection guidelines: A study using the theoretical domains framework",

abstract = "Strong evidence supports the use of antenatal magnesium sulphate before birth at less than 30 weeks{\textquoteright} gestation to reduce the risk of death and cerebral palsy for very preterm babies. This study was undertaken to assess health professionals{\textquoteright} self reported use of this neuroprotective therapy, and barriers and enablers to implementation of Australian and New Zealand clinical practice guidelines.",

keywords = "fetal neuroprotection, Antenatal care, magnesium sulphate, neuroprotective therapy",

author = "Emily Bain and Tanya Bubner and Philippa Middleton and Pat Ashwood and {Van Ryswyk}, Emer and Lucy Simmons and Sally Reid and Crowther, {Caroline A}",

year = "2015",

month = apr,

doi = "10.1111/jpc.12884_2",

language = "English",

volume = "51",

pages = "30",

journal = "Journal of Paediatrics and Child Health",

issn = "1440-1754",

publisher = "Blackwell Science Asia",

number = "Suppl 1",

note = "Perinatal Society of Australia and New Zealand 19th Annual Congress, PSANZ ; Conference date: 19-04-2015 Through 22-04-2015",

}

Barriers and enablers to implementing antenatal magnesium sulphate for fetal neuroprotection guidelines: A study using the theoretical domains framework. / Bain, Emily; Bubner, Tanya; Middleton, Philippa et al.
In: Journal of Paediatrics and Child Health, Vol. 51, No. Suppl 1, 04.2015, p. 30.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Barriers and enablers to implementing antenatal magnesium sulphate for fetal neuroprotection guidelines: A study using the theoretical domains framework

AU - Bain, Emily

AU - Bubner, Tanya

AU - Middleton, Philippa

AU - Ashwood, Pat

AU - Van Ryswyk, Emer

AU - Simmons, Lucy

AU - Reid, Sally

AU - Crowther, Caroline A

N1 - Conference code: 19

PY - 2015/4

Y1 - 2015/4

N2 - Strong evidence supports the use of antenatal magnesium sulphate before birth at less than 30 weeks’ gestation to reduce the risk of death and cerebral palsy for very preterm babies. This study was undertaken to assess health professionals’ self reported use of this neuroprotective therapy, and barriers and enablers to implementation of Australian and New Zealand clinical practice guidelines.

AB - Strong evidence supports the use of antenatal magnesium sulphate before birth at less than 30 weeks’ gestation to reduce the risk of death and cerebral palsy for very preterm babies. This study was undertaken to assess health professionals’ self reported use of this neuroprotective therapy, and barriers and enablers to implementation of Australian and New Zealand clinical practice guidelines.

KW - fetal neuroprotection

KW - Antenatal care

KW - magnesium sulphate

KW - neuroprotective therapy

U2 - 10.1111/jpc.12884_2

DO - 10.1111/jpc.12884_2

M3 - Meeting Abstract

SN - 1440-1754

VL - 51

SP - 30

JO - Journal of Paediatrics and Child Health

JF - Journal of Paediatrics and Child Health

IS - Suppl 1

T2 - Perinatal Society of Australia and New Zealand 19th Annual Congress

Y2 - 19 April 2015 through 22 April 2015

ER -

Barriers and enablers to implementing antenatal magnesium sulphate for fetal neuroprotection guidelines: A study using the theoretical domains framework

Abstract

Keywords

Access to Document

Fingerprint

Cite this